Adlinameg Tablet 2.5 mg + 850 mg is a combination oral antidiabetic medication containing Linagliptin 2.5 mg and Metformin Hydrochloride 850 mg. It is specifically designed for adults with type 2 diabetes mellitus who require enhanced glycemic control that cannot be achieved with diet, exercise, or monotherapy alone. By combining two complementary mechanisms of action in a single tablet, Adlinameg 2.5 mg + 850 mg helps maintain stable blood glucose levels and reduces the risk of long-term diabetes-related complications.

This tablet is part of a comprehensive diabetes management plan, which includes lifestyle modification, dietary control, regular physical activity, and periodic monitoring of blood glucose and HbA1c levels. The combination of linagliptin and metformin provides effective, convenient, and safe glycemic control in one daily dose.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Linagliptin 2.5 mg

• Metformin Hydrochloride 850 mg

Mechanism of Action

Adlinameg combines the complementary effects of a DPP-4 inhibitor (Linagliptin) and a biguanide (Metformin) to control blood glucose through multiple pathways:

Linagliptin
Linagliptin inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which breaks down incretin hormones such as GLP-1 and GIP. By preserving these hormones, linagliptin enhances glucose-dependent insulin secretion and suppresses postprandial glucagon release, effectively reducing post-meal blood glucose elevations.

Metformin Hydrochloride
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, promoting better glucose utilization. Unlike sulfonylureas, metformin does not increase insulin secretion, which lowers the risk of hypoglycemia when used alone.

Together, these two actions provide comprehensive glycemic control, addressing both insufficient insulin response and excessive hepatic glucose production, which are key contributors to type 2 diabetes.

Indications

Adlinameg Tablet 2.5 mg + 850 mg is indicated for:

• Management of Type 2 Diabetes Mellitus in adults

• Patients inadequately controlled with diet and exercise alone

• Patients requiring combination therapy for improved blood sugar management

• Use alongside lifestyle modifications to reduce the risk of long-term diabetes complications

Benefits

• Dual Mechanism of Action: Targets both insulin secretion and hepatic glucose production

• Effective Glycemic Control: Reduces fasting and postprandial blood glucose levels

• HbA1c Reduction: Helps achieve long-term glycemic targets

• Low Risk of Hypoglycemia: Particularly when not combined with insulin or sulfonylureas

• Weight Neutral: Linagliptin is weight neutral, and metformin may support modest weight loss

• Convenient Single Tablet Therapy: Improves patient adherence by combining two antidiabetic agents

Dosage and Administration

Adlinameg Tablet 2.5 mg + 850 mg is usually taken once or twice daily with meals to reduce gastrointestinal side effects associated with metformin. The exact dosage should be tailored by a healthcare professional based on blood glucose levels, kidney function, and patient response.

Patients should maintain adequate hydration, adhere to dietary recommendations, and regularly monitor blood glucose and HbA1c for optimal results.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Safety and Precautions

• Not indicated for Type 1 diabetes or diabetic ketoacidosis

• Use with caution in patients with renal or hepatic impairment

• Metformin may cause mild gastrointestinal discomfort, nausea, or diarrhea, especially when initiating therapy

• Rare risk of lactic acidosis exists; seek immediate medical attention if symptoms such as severe fatigue, abdominal pain, or breathing difficulties occur

• Linagliptin may rarely cause mild headache or nasopharyngitis

• Inform your healthcare provider about all medications and medical conditions before starting therapy.